Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a <i>post hoc</i> analysis of JCOG1213.

ESMO Gastrointest Oncol · 2025 · PMC12836487 · PMID 41646270

Europe PMC DOI

hedged sentence

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

did not reach statistical significanceP = 0.0720so close (0.05 < p ≤ 0.1)

There was a trend toward shorter OS in patients with liver metastasis although the difference did not reach statistical significance (HR 1.434, 95% CI 0.968-2.124, P = 0.0720, Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a &lt;i&gt;post hoc&lt;/i&gt; analysis of JCOG1213.

The sentences

Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a <i>post hoc</i> analysis of JCOG1213.